Cynanbungeigenin C (CBC) and D (CBD) / HO-1 Cancer Research Results

CBC/D, Cynanbungeigenin C (CBC) and D (CBD): Click to Expand ⟱
Features:

Cynanbungeigenin C and D — Cynanbungeigenin C (CBC) and Cynanbungeigenin D (CBD) are a pair of epimeric C21 steroidal natural products isolated from Cynanchum bungei Decne. They are best classified as plant-derived small-molecule Hedgehog pathway inhibitors, with reported activity at or near the GLI transcriptional effector level rather than as canonical Smoothened-only inhibitors. The abbreviation CBC/D is preferable in this database entry because CBC and CBD also commonly refer to cannabinoids.

Primary mechanisms (ranked):

  1. Hedgehog pathway suppression through GLI-level blockade, reducing downstream GLI1-dependent transcriptional output.
  2. Suppression of Hedgehog-dependent medulloblastoma growth and tumor-propagating signaling.
  3. Anti-proliferative and pro-apoptotic tumor effects, strongest evidence currently from medulloblastoma models for CBC/D and colorectal cancer models for the CBC derivative CBC-1.
  4. Drug-development constraint: poor aqueous solubility of parent CBC, motivating CBC-1 derivative synthesis with improved solubility and stronger colorectal cancer activity.

Bioavailability / PK relevance: Human pharmacokinetics, oral bioavailability, metabolism, and clinically achievable exposure are not established. Parent CBC has reported poor water solubility; CBC-1 was developed partly to improve this limitation. Mouse in-vivo activity is preclinical and should not be treated as evidence of human exposure feasibility.

In-vitro vs systemic exposure relevance: The mechanistic evidence is concentration-driven and mostly preclinical. Because human PK data are absent, common in-vitro concentrations cannot yet be judged against achievable systemic exposure. Solubility and formulation are central translation constraints.

Clinical evidence status: Preclinical only. Evidence consists mainly of natural-product isolation, cell-based Hedgehog/GLI assays, medulloblastoma tumor models, and a newer CBC-derived GLI1 inhibitor study in colorectal cancer. No human oncology trials or regulatory approval were identified for CBC/D or CBC-1.

CBC/D Cancer Mechanism Matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 GLI transcriptional output ↓ GLI signaling Not established G Blocks Hedgehog signaling at the GLI level Core mechanism for CBC/D in Hedgehog-dependent medulloblastoma; CBC-1 derivative evidence supports direct GLI1 targeting in CRC models.
2 Hedgehog pathway ↓ HH pathway activity Not established G Suppresses oncogenic HH pathway dependence Most relevant where tumors depend on SHH/HH-GLI signaling; likely context-dependent across cancers.
3 Medulloblastoma growth ↓ proliferation and tumor growth Not established G Antitumor activity in HH-dependent medulloblastoma models Parent CBC/D evidence is strongest in this disease model rather than broad pan-cancer evidence.
4 Apoptosis ↑ apoptosis Not established G Cell death secondary to GLI1 suppression Best documented for CBC-1 derivative in colorectal cancer; parent CBC/D apoptosis evidence should be marked derivative-supported unless confirmed in the original paper.
5 Tumor progression ↓ tumor-propagating capacity Not established G Reduced malignant growth phenotype tumor cell proliferation or tumor progression suppression; external evidence supports growth suppression more clearly than migration-specific effects.
6 ROS NRF2 Ca²⁺ Glycolysis HIF-1α Not established Not established G No primary evidence found Do not force redox, NRF2, calcium, glycolysis, or hypoxia axes unless a direct CBC/D paper supports them.
7 Clinical Translation Constraint Solubility-limited parent compound Safety window not established G PK and formulation uncertainty Parent CBC poor water solubility and absent human PK are the main database constraints; CBC-1 derivative improves solubility but remains preclinical.

TSF legend:

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
HO-1, HMOX1: Click to Expand ⟱
Source:
Type:
(Also known as Hsp32 and HMOX1)
HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene.
HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer.
-widely regarded as having antioxidant and cytoprotective effects
-The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage

Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by:
  Reducing oxidative stress and inflammation
  Promoting angiogenesis (the formation of new blood vessels)
  Inhibiting apoptosis (programmed cell death)
  Enhancing cell migration and invasion
When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions.

A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1.

-Curcumin   Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects.
-Resveratrol  Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties.
-Quercetin   Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses.
-EGCG     Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties.
-Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes.
-Luteolin    Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models.
-Apigenin   Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities.
Scientific Papers found: Click to Expand⟱
6254- CBC/D,    Cynanchum auriculatum Royle ex Wight., Cynanchum bungei Decne. and Cynanchum wilfordii (Maxim.) Hemsl.: Current Research and Prospects
- Review, Var, NA
*neuroP↑, *Imm↑, *Inflam↓, CSCs↓, HH↓, Gli↓, AST↓, ALAT↓, MDA↓, hepatoP↑, *NRF2↑, *HO-1↑, NF-kB?, GSK‐3β↓, β-catenin/ZEB1↓, COX2↓, MMP2↑, MMP9↓, BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

MDA↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   Gli↓, 1,   GSK‐3β↓, 1,   HH↓, 1,  

Migration ⓘ

MMP2↑, 1,   MMP9↓, 1,   β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   NF-kB?, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   NRF2↑, 1,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 1,   Inflam↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,  
Total Targets: 5

Scientific Paper Hit Count for: HO-1, HMOX1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:67  Target#:597  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page